REQUIP XL SUMMARY
REQUIP (ropinirole) and REQUIP XL (ropinirole extended release) is an orally administered non-ergoline dopamine agonist.
REQUIP XL (ropinirole extended-release tablets) is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
|
|
NEWS HIGHLIGHTSMedia Articles Related to Requip XL (Ropinirole)
Parkinson's Disease Quiz: Test Your Medical IQ Source: MedicineNet Dementia Specialty [2017.09.19] Title: Parkinson's Disease Quiz: Test Your Medical IQ Category: MedicineNet Quiz Created: 8/23/2011 12:53:00 PM Last Editorial Review: 9/19/2017 6:54:29 PM
Parkinson's Disease and Melanoma May Occur Together, Study Finds Source: MedicineNet Melanoma Specialty [2017.07.10] Title: Parkinson's Disease and Melanoma May Occur Together, Study Finds Category: Health News Created: 7/7/2017 12:00:00 AM Last Editorial Review: 7/10/2017 12:00:00 AM
Hepatitis Infection May Raise Risk for Parkinson's Disease Source: MedicineNet Tremor Specialty [2017.03.31] Title: Hepatitis Infection May Raise Risk for Parkinson's Disease Category: Health News Created: 3/30/2017 12:00:00 AM Last Editorial Review: 3/31/2017 12:00:00 AM
Parkinson's Disease Source: MedicineNet amantadine Specialty [2016.08.09] Title: Parkinson's Disease Category: Diseases and Conditions Created: 12/31/1997 12:00:00 AM Last Editorial Review: 8/9/2016 12:00:00 AM
Parkinson's Disease: Symptoms, Causes, Stages, Treatment Source: MedicineNet rivastigmine Specialty [2016.06.01] Title: Parkinson's Disease: Symptoms, Causes, Stages, Treatment Category: Slideshows Created: 8/16/2011 6:25:00 PM Last Editorial Review: 6/1/2016 12:00:00 AM
Published Studies Related to Requip XL (Ropinirole)
Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double-blind
study. [2014] (PD) patients on concomitant levodopa therapy... CONCLUSIONS: Rotigotine was well tolerated at doses up to 16 mg/24 h and showed
[Efficacy and safety of ropinirole in the treatment of Parkinson's disease: a
multi-center, randomized, double-blind and bromocriptine-controlled trial]. [Article in Chinese] [2013] Parkinson's disease... CONCLUSIONS: Ropinirole is both effective and safe in the treatment of Chinese
The efficacy and safety of ropinirole prolonged release tablets as adjunctive
therapy in Chinese subjects with advanced Parkinson's disease: a multicenter,
double-blind, randomized, placebo-controlled study. [2013] Parkinson's disease (PD) not optimally controlled with L-dopa... CONCLUSIONS: This study demonstrated for the first time in Chinese subjects that
PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. [2011.06] BACKGROUND: PREPARED was a randomized, parallel-group, double-blind, multicenter study to evaluate the efficacy of adjunctive ropinirole prolonged release (PR) versus immediate release (IR) in patients with advanced Parkinson's disease (PD)... CONCLUSIONS: Adjunctive PR provided a significantly greater improvement in symptom control in terms of the odds of achieving >/= 20% maintained reduction in time spent "off" compared with IR. Interpretation may be confounded by the higher doses of PR versus IR that were achieved, in combination with lower doses of L-dopa by the study end. Despite dosing differences, the PR titration regimen was generally well tolerated, with an AE profile similar to that of IR. Copyright (c) 2011 Movement Disorder Society.
Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study. [2011.06] Comorbid depressive symptoms in restless legs syndrome (RLS) remain a treatment challenge, as some antidepressants aggravate RLS symptoms...
Clinical Trials Related to Requip XL (Ropinirole)
REQUIP RLS Post Marketing Surveillance [Completed]
Two Way Cross Over BE Fasting Pilot Study of Ropinirole Hydrochloride CR 2mg Tablets [Completed]
Study subjects were screened and enrolled for the study. Subjects were housed in the
clinical facility from not less than 12 hours pre-dose till at least 24 hours post-dose in
each period. After maintaining at least 10 hours of overnight fast Test or Reference product
was administered orally (as per the randomization schedule) to each subject with about 240
mL of water at ambient temperature in each period by trained study personnel.
The pre-dose (0. 00 hours) blood sample was collected before dosing and post-dose samples
were collected at 2. 00, 3. 00, 4. 00, 5. 00, 5. 50, 6. 00, 6. 50, 7. 00, 7. 50, 8. 00, 8. 50, 9. 00,
9. 50, 10. 00, 10. 50, 11. 00, 12. 00, 14. 00, 16. 00, 20. 00, 24. 00 and 30. 00 hours in each study
period with a washout period of 7 days between the dosing of two periods. Subjects were
continuously monitored for well being i. e., blood pressure, radial pulse and oral
temperature before check-in, prior to drug administration and at regular intervals post dose
in each period. The concentration of Ropinirole in plasma samples obtained from study
subjects was determined using validated LC-MS/MS method. Pharmacokinetic and statistical
analyses were performed on obtained drug concentration data, using appropriate software.
Bioequivalence Study of Ropinirole Hydrochloride CR 2mg Tablets of Lupin Limited, India, With REQUIP XL of GlaxoSmithKline Research Triangle Park, in Healthy, Adult, Male, Subjects Under Fasting Conditions [Completed]
Study subjects were screened and enrolled for the study. Subjects were housed in the
clinical facility from not less than 12 hours pre-dose till at least 30 hours post-dose in
each period. After maintaining at least 10 hours of overnight fast Test or Reference product
was administered orally (as per the randomization schedule) to each subject with about 240
mL of water at ambient temperature in each period by trained study personnel.
The pre-dose (0. 00 hours) blood sample was collected before dosing and post-dose samples
were collected at 2. 00, 3. 00, 4. 00, 5. 00, 5. 50, 6. 00, 6. 50, 7. 00, 7. 50, 8. 00, 8. 50, 9. 00,
9. 50, 10. 00, 10. 50, 11. 00, 12. 00, 14. 00, 16. 00, 20. 00, 24. 00 and 30. 00 hours in each study
period with a washout period of 7 days between the dosing of two periods. Subjects were
continuously monitored for well being i. e., blood pressure, radial pulse and oral
temperature before check-in, prior to drug administration and at regular intervals post dose
in each period. The concentration of Ropinirole in plasma samples obtained from study
subjects was determined using validated LC-MS/MS method. Pharmacokinetic and statistical
analyses were performed on obtained drug concentration data, using appropriate software.
Bioequivalence Study of Ropinirole Hydrochloride CR 2mg Tablets of Lupin Limited, India, With REQUIP XL of GlaxoSmithKline Research Triangle Park, in Healthy, Adult, Male, Subjects Under Fed Conditions [Completed]
Study subjects were screened and enrolled for the study. Subjects were housed in the
clinical facility from not less than 12 hours pre-dose till at least 30 hours post-dose in
each period. After maintaining at least 10 hours of overnight fast Test or Reference product
was administered orally (as per the randomization schedule) to each subject with about 240
mL of water at ambient temperature in each period by trained study personnel after consuming
the whole standardized high fat non-veg breakfast.
The pre-dose (0. 00 hours) blood sample was collected before dosing and post-dose samples
were collected at 2. 00, 3. 00, 4. 00, 5. 00, 6. 00, 7. 00, 7. 50, 8. 00, 8. 50, 9. 00, 9. 50, 10. 00,
10. 50, 11. 00, 11. 50, 12. 00, 12. 50, 13. 00, 14. 00, 16. 00, 20. 00, 24. 00 and 30. 00 hours in each
study period with a washout period of 7 days between the dosing of two periods. Subjects
were continuously monitored for well being i. e., blood pressure, radial pulse and oral
temperature before check-in, prior to drug administration and at regular intervals post dose
in each period. The concentration of Ropinirole in plasma samples obtained from study
subjects was determined using validated LC-MS/MS method. Pharmacokinetic and statistical
analyses were performed on obtained drug concentration data, using appropriate software.
Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528 [Completed]
This open label extension study allows assessment of the long term safety profile of REQUIP
PR in subjects who have completed 24 weeks of randomised treatment in study ROP111528.
Subjects must not have a break in study medication between completing the feeder study and
entering extension study, treatment must be continuous.
Subjects will be dispensed down-titration medication at the study completion/early
withdrawal visit and should be scheduled to return for a follow up visit 4 to 14 days after
the last dose of study medication.
Reports of Suspected Requip XL (Ropinirole) Side Effects
Medication Residue (8),
Somnolence (7),
Drug Ineffective (6),
OFF Label USE (6),
Drug Administration Error (5),
Hallucination (5),
Nausea (5),
Hallucination, Visual (5),
Insomnia (5),
Malaise (4), more >>
|
|
Page last updated: 2017-09-19
|